TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product-Reference-Cited by-同舟云学术

TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product

Published:2020-02 Issue:2 Volume:28 Page:561-571
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Straetemans Trudy,Janssen Anke,Jansen Koen,Doorn Ruud,Aarts Tineke,van Muyden Anna D.D.,Simonis Marieke,Bergboer Judith,de Witte Moniek,Sebestyen Zsolt,Kuball Jurgen

Funder

ZonMw

KWF Kankerbestrijding

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference59 articles.

1. Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies;Chabannon;Sci. Transl. Med.,2018

2. Chimeric Antigen Receptor Therapy;June;N. Engl. J. Med.,2018

3. T-cell receptor-engineered T cells for cancer treatment: current status and future directions;Ping;Protein Cell,2018

4. Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor;Marcu-Malina;Blood,2011

5. γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs;Gründer;Blood,2012

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Basics of advanced therapy medicinal product development in academic pharma and the role of a GMP simulation unit;Immuno-Oncology and Technology;2023-12

2. Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds;Journal for ImmunoTherapy of Cancer;2021-11

3. Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control;Frontiers in Immunology;2021-10-25

4. Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia;Cancers;2021-09-08

5. Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells;Molecular Therapy - Methods & Clinical Development;2021-09